Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIMMUNE THERAPEUTICS PLC

(ADAP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Adaptimmune Therapeutics : June 2021 Corporate Deck

06/01/2021 | 09:41am EDT

Corporate Deck June 2021

Disclaimer

This presentation contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect" and other words of similar meaning. These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials; our ability to submit an IND and successfully advance our technology platform to improve the safety and effectiveness of our existing TCR therapeutic candidates; the rate and degree of market acceptance of T-cell therapy generally and of our TCR therapeutic candidates; government regulation and approval, including, but not limited to, the expected regulatory approval timelines for TCR therapeutic candidates; and our ability to protect our proprietary technology and enforce our intellectual property rights; amongst others. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2021 and our other SEC filings.

We urge you to consider these factors carefully in evaluating the forward-looking statements herein and you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements contained in this presentation speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

2

Our vision and mission - Arming cell therapies to target solid tumors

Arming Cells.

Against Cancer.

For Good.

To transform the lives of people with cancer by designing and delivering cell therapies

3

Our 5-year core value drivers

4

5-year core value drivers: our "2-2-5-2" plan

TwoTwoFive

marketed

additional BLAs

autologous

SPEAR T-cell

for SPEAR T-cell

products in the

products targeting

products

clinic

MAGE-A4

Synovial sarcoma

Additional indications

HiT

and MRCLS

for MAGE-A4

• Next-gen TILs

targeted products

Esophageal and

New targets

EGJ cancers

ADP-A2AFP

Broader HLA

coverage

Two

allogeneic products entering the clinic

  • SPEAR T-cell product targeting MAGE-A4
  • HiT mesothelin - partnered with Astellas

Integrated Cell Therapy Capabilities

Research | Preclinical | Translational | Clinical | CMC | Regulatory | Commercial

5 EGJ: esophagogastric junction cancer; HiT: HLA-independentT-cell receptor (TCR); TIL: tumor infiltrating lymphocyte; CMC: chemistry, manufacturing, and controls

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Adaptimmune Therapeutics plc published this content on 01 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 June 2021 13:40:06 UTC.


ę Publicnow 2021
All news about ADAPTIMMUNE THERAPEUTICS PLC
08/03European ADRs Move Higher in Tuesday Trading
MT
07/28Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday..
GL
07/22European ADRs Modestly Lower Thursday as Unilever Slides
MT
07/21European ADRs Move Sharply Higher in Wednesday Trading
MT
07/20European ADRs Up 0.5% Tuesday
MT
07/07European ADRs Nearly Flat Wednesday as Miners, Techs Gain
MT
07/02European ADRs Move Lower in Friday Trading
MT
06/30European ADRs Move Lower in Wednesday Trading
MT
06/23European ADRs Edge Higher in Wednesday Trading
MT
06/18European ADRs Down More Than 2% Friday as Banks, Drillers Drop
MT
More news
Financials (USD)
Sales 2021 2,61 M - -
Net income 2021 -159 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,45x
Yield 2021 -
Capitalization 535 M 535 M -
Capi. / Sales 2021 205x
Capi. / Sales 2022 29,4x
Nbr of Employees 462
Free-Float 7,23%
Chart ADAPTIMMUNE THERAPEUTICS PLC
Duration : Period :
Adaptimmune Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIMMUNE THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 3,44 $
Average target price 9,50 $
Spread / Average Target 176%
EPS Revisions
Managers and Directors
Adrian Rawcliffe Chief Executive Officer & Director
Gavin Wood Chief Financial Officer
David M. Mott Chairman
Elliot Norry Chief Medical Officer
William C. Bertrand Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ADAPTIMMUNE THERAPEUTICS PLC-36.18%535
BIONTECH SE408.39%100 096
GILEAD SCIENCES, INC.19.86%86 839
WUXI APPTEC CO., LTD.43.36%72 049
REGENERON PHARMACEUTICALS21.40%60 161
VERTEX PHARMACEUTICALS-15.55%51 779